<br>表没食子儿茶素没食子酸酯 (EGCG) 从三维打印 (3DP) 磷酸钙骨支架中释放的体外生物学评价,Journal of Materials Chemistry B

当前位置： X-MOL 学术 › J. Mater. Chem. B › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

表没食子儿茶素没食子酸酯 (EGCG) 从三维打印 (3DP) 磷酸钙骨支架中释放的体外生物学评价
Journal of Materials Chemistry B ( IF 6.1 ) Pub Date : 2022-12-21 , DOI: 10.1039/d2tb02210a
Yongdeok Jo ₁ , Naboneeta Sarkar ₁ , Susmita Bose ₁

Affiliation

三维打印 (3DP) 磷酸三钙 (TCP) 支架可以引导骨再生，特别适用于低承载部位的特定患者缺损修复应用。表没食子儿茶素没食子酸酯 (EGCG) 是一种绿茶化合物，作为治疗骨骼疾病的更安全的替代疗法而受到关注。 3DP TCP支架设计用于局部EGCG递送，可以增强体外成骨能力、抗破骨活性、血管形成和化学预防。在人骨髓间充质干细胞 (hMSC) 和单核细胞 (THP-1) 的共培养中，与对照相比，第 16 天时 EGCG 的释放增强了 hMSC 的成骨分化； Runt 相关转录因子 2 (Runx2) 和骨 γ-羧基谷氨酸含蛋白 (BGLAP)（早期和晚期成骨细胞分化标志物表达）的 2.8 倍和 4.0 倍上调表明了这一点。然而，EGCG 显着下调核因子-κB 配体受体激活剂 (RANKL) 的表达达 7.0 倍，表明 EGCG 抑制 RANKL 诱导的破骨细胞成熟。当人脐静脉内皮细胞 (HUVEC) 在基质胶上生长 3 小时时，EGCG 还可刺激内皮管形成。与第 11 天的对照相比，它使人骨肉瘤 MG-63 细胞活力降低 66%。体外释放动力学研究表明，EGCG 在一天内释放约 64%，随后在生理环境（pH 7.4）中持续释放）因为其酚羟基在生理pH值下很容易去质子化。这些发现有助于开发一种多功能支架，用于治疗创伤和肿瘤切除后低承重患者特异性骨缺损。

"点击查看英文标题和摘要"

In vitro biological evaluation of epigallocatechin gallate (EGCG) release from three-dimensional printed (3DP) calcium phosphate bone scaffolds

Three-dimensional printed (3DP) tricalcium phosphate (TCP) scaffolds can guide bone regeneration, especially for patient-specific defect repair applications in low-load bearing sites. Epigallocatechin gallate (EGCG), a green tea compound, has gained attention as a safer alternative treatment for bone disorders. The 3DP TCP scaffold is designed for localized EGCG delivery, which can enhance in vitro osteogenic ability, anti-osteoclastogenic activity, vascularization formation, and chemoprevention. In the cocultures of human bone marrow-derived mesenchymal stem cells (hMSCs) and monocytes (THP-1), EGCG release enhances osteogenic differentiation of hMSCs at day 16 compared to the control; this is indicated by a 2.8- and 4.0-fold upregulation of Runt-related transcription factor 2 (Runx2) and bone gamma-carboxyglutamic acid-containing protein (BGLAP), the early and late osteoblast differentiation marker expressions. However, EGCG significantly downregulates the receptor activator of nuclear factor-κB ligand (RANKL) expression by 7.0-fold, indicating that EGCG suppresses RANKL-induced osteoclast maturation. EGCG also stimulates endothelial tube formation at as early as 3 hours when human umbilical vein endothelial cells (HUVECs) grow on Matrigel. It reduces human osteosarcoma MG-63 cell viability by 66% compared to the control at day 11. An in vitro release kinetics study demonstrates that EGCG shows a ∼64% release within a day followed by a sustained release in the physiological environment (pH 7.4) because its phenolic hydroxyl groups are easily deprotonated at physiological pH. These findings contribute to developing a multifunctional scaffold for the treatment of low load-bearing patient-specific bone defects after trauma and tumor excision.

更新日期：2022-12-21

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南